CÁNCER DE MAMA
![Foto de CÁNCER DE MAMA](/img/grupo.png)
![Foto de Hospital Universitari de Girona Dr. Josep Trueta](/img/noimage_org.png)
Hospital Universitari de Girona Dr. Josep Trueta
Girona, EspañaPublications en collaboration avec des chercheurs de Hospital Universitari de Girona Dr. Josep Trueta (8)
2019
-
Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients
Aging, Vol. 11, Núm. 9, pp. 2874-2888
-
Neoadjuvant metformin added to systemic therapy decreases the proliferative capacity of residual breast cancer
Journal of Clinical Medicine, Vol. 8, Núm. 12
-
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study
Breast Cancer Research and Treatment, Vol. 177, Núm. 1, pp. 115-125
-
The C allele of ATM rs11212617 associates with higher pathological complete remission rate in breast cancer patients treated with neoadjuvant metformin
Frontiers in Oncology, Vol. 9, Núm. MAR
2018
-
A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: The METTEN study
Oncotarget, Vol. 9, Núm. 86, pp. 35687-35704
2014
-
Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors
Medical Oncology, Vol. 31, Núm. 1
-
VAV3 mediates resistance to breast cancer endocrine therapy
Breast Cancer Research, Vol. 16, Núm. 3
2013
-
Basal/HER2 breast carcinomas Integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin)
Cell Cycle, Vol. 12, Núm. 2, pp. 225-245